Lifecore Biomedical (LFCR) AI Stock Analysis

• Market Cap: $254.02M
• Dividend Yield: N/A
• Average Volume (3M): 204.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: 0.47%
• EPS Growth: -430.88%
• Country: US
• Employees: 524
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.29
• Shares Outstanding: 37,466,350
• 10 Day Avg. Volume: 178,832
• 30 Day Avg. Volume: 204,257
• PEG Ratio: 0.01
• Price to Book (P/B): 4.93
• Price to Sales (P/S): 1.82
• P/FCF Ratio: -17.18
• Enterprise Value/Market Cap: 1.65
• Enterprise Value/Revenue: 3.10
• Enterprise Value/Gross Profit: 9.81
• Enterprise Value/Ebitda: -59.46
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $8.00 ▲(2.30% Upside)

Lifecore Biomedical's overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and profitability issues. While technical analysis shows bullish momentum, the overbought RSI suggests caution. The negative P/E ratio further highlights valuation concerns. Strategic improvements in financial management are necessary to enhance the company's stability and attractiveness.

Positive Factors

Strategic Growth Plan

Lifecore's strategic focus on maximizing existing business, advancing late-stage programs, and winning new business supports long-term revenue growth and margin expansion.

Partnerships and Collaborations

Strategic partnerships enhance Lifecore's product offerings and market reach, leveraging its CDMO capabilities to drive consistent revenue and growth.

Revenue Growth

Exceeding revenue expectations indicates strong market demand and effective execution of growth strategies, supporting future financial stability.

Negative Factors

Declining Profitability

Persistent losses and declining revenue highlight challenges in achieving sustainable profitability, impacting long-term financial health.

High Leverage

High leverage indicates significant reliance on debt financing, posing risks to financial stability and limiting flexibility in capital allocation.

Negative Cash Flow

Negative operating cash flow suggests operational inefficiencies and challenges in sustaining business operations without external financing.

Lifecore Biomedical Business Overview & Revenue Model

Company Description

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

How the Company Makes Money

Lifecore Biomedical generates revenue through multiple streams, primarily driven by the sale of its specialized hyaluronic acid products to healthcare providers and distributors. The company has established significant partnerships with medical device companies and pharmaceutical firms, allowing it to leverage its manufacturing capabilities for contract development and manufacturing services (CDMO). This collaboration not only enhances Lifecore's product offerings but also contributes to consistent revenue through service contracts. Additionally, the company benefits from a growing demand for its aesthetic products, particularly in the cosmetic dermatology market, as consumer interest in non-surgical treatments continues to rise.

Lifecore Biomedical Financial Statement Overview

Summary

Lifecore Biomedical faces significant financial challenges, with high leverage and ongoing profitability issues. While there is some revenue growth, the company struggles to convert this into positive net income and cash flow. The financial position indicates potential risks, requiring strategic improvements in cost management and debt reduction to enhance stability and profitability.

Income Statement

Lifecore Biomedical shows a modest revenue growth rate of 4.97% TTM, indicating some positive momentum. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively stable at 31.27%, but overall profitability remains a concern due to consistent net losses.

Balance Sheet

The balance sheet reflects high leverage with a debt-to-equity ratio of 2.76, indicating significant reliance on debt financing. The negative return on equity suggests that the company is not generating sufficient returns on shareholders' investments. The equity ratio is low, highlighting potential financial instability.

Cash Flow

Cash flow analysis reveals challenges, with negative free cash flow growth and a low operating cash flow to net income ratio. Despite these issues, the free cash flow to net income ratio is relatively high, suggesting some efficiency in converting net income to cash flow. However, overall cash flow management needs improvement.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	135.27M	128.87M	128.26M	103.27M	111.27M	100.87M
Gross Profit	42.70M	40.30M	41.85M	27.98M	39.07M	38.94M
EBITDA	-7.04M	-8.81M	35.60M	-33.17M	12.84M	-987.00K
Net Income	-32.48M	-38.72M	12.01M	-99.56M	-116.72M	-32.29M
Balance Sheet
Total Assets	235.20M	239.34M	253.96M	253.54M	274.70M	502.92M
Cash, Cash Equivalents and Short-Term Investments	18.86M	8.27M	8.46M	19.09M	991.00K	1.16M
Total Debt	137.53M	130.82M	133.57M	112.62M	247.78M	215.86M
Total Liabilities	198.42M	238.01M	242.65M	257.77M	186.88M	300.14M
Stockholders Equity	36.79M	1.34M	11.31M	-4.23M	87.82M	202.78M
Cash Flow
Free Cash Flow	-9.56M	-13.62M	-18.14M	-38.92M	-52.53M	-8.75M
Operating Cash Flow	2.20M	-206.00K	257.00K	-17.44M	-22.59M	16.47M
Investing Cash Flow	-4.76M	-6.42M	-18.39M	-4.81M	79.96M	-12.31M
Financing Cash Flow	3.94M	6.42M	7.51M	39.70M	-57.02M	-3.42M

Lifecore Biomedical Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFCR, the sentiment is Positive. The current price of 7.82 is above the 20-day moving average (MA) of 7.51, above the 50-day MA of 7.15, and above the 200-day MA of 7.01, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 57.73 is Neutral, neither overbought nor oversold. The STOCH value of 68.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LFCR.

Lifecore Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DERM	57 Neutral	$207.05M	―	-47.05%	―	2.82%	60.26%
IRWD	54 Neutral	$311.87M	―	―	―	-10.42%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CPIX	51 Neutral	$39.79M	-12.47	-13.08%	―	12.21%	69.91%
LFCR	48 Neutral	$254.02M	-5.20	―	―	0.47%	-430.88%
BIOA	33 Underperform	$267.80M	-3.34	-25.64%	―	―	―

Lifecore Biomedical Corporate Events

Lifecore Biomedical Reports Strong Revenue Growth

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization specializing in the development, fill, and finish of sterile injectable pharmaceutical products, with a strong focus on hyaluronic acid manufacturing for global biopharmaceutical companies.

Lifecore Biomedical Approves Key Proposals at Annual Meeting

On October 29, 2025, Lifecore Biomedical held its annual meeting of stockholders, where three key proposals were addressed. Stockholders elected nine directors, ratified the appointment of KPMG LLP as the independent auditor for the fiscal year ending December 31, 2025, and approved the executive compensation package. These decisions are expected to influence the company’s governance and financial oversight, potentially impacting its strategic direction and stakeholder confidence.

The most recent analyst rating on (LFCR) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Lifecore Biomedical stock, see the LFCR Stock Forecast page.

Lifecore Biomedical Approves New Cash Incentive Plan

On September 22, 2025, Lifecore Biomedical‘s Compensation Committee approved a new cash incentive pay plan for the period from May 26, 2025, to December 31, 2025, due to a fiscal year change. This plan replaces the previously approved 2026 Bonus Plan and is designed to align executive bonuses with company financial performance goals, such as Adjusted EBITDA and total revenue, with a maximum bonus cap of 200% of the target level.

The most recent analyst rating on (LFCR) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Lifecore Biomedical stock, see the LFCR Stock Forecast page.